Circle Pharma Announces Nomination of CID-165, an Oral First-in-class Cyclin D1 RxL Inhibitor, as Development Candidate for its Second Oncology Program Circle Pharma, Inc., a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback